Immunoproteins are significant in initiating an immune reaction against an antigen. These immunoproteins display a negligible serum level in ordinary conditions, but on revelation to an antigen, their levels upsurge 10 to 100 times within 24 to 48 hours. This distinguishing property of immunoproteins has been browbeaten in the area of disease identification and has nowadays turned out to be an essential part of the healthcare segment.
With the escalating frequencies of diseases such as diabetes, cancer, tuberculosis, malaria, and innumerable viral infections, speedy and deep-rooted diagnosis has become a key necessity in hospitals and diagnostic centers globally. The geriatric population has added to the sum of individuals looking for medical care and is predicted to carry on increasing in the future. Furthermore, the occurrence of allergies and autoimmune diseases whose identification is even more serious is also on the upswing. The combined consequence of these occurrences will thrust the immunoprotein diagnostic testing market to grow at a CAGR of 5.7% till 2019.
The demand for immunoprotein diagnostic testing is uninterruptedly growing with developments in technology and development of innovative products, expanding the space of market. Innovations and new developments have occasioned in the broadening of the execution areas of immunoprotein diagnostic testing like oncology, allergy testing, infectious disease testing, and drug abuse testing. Recently, the concentrated research and development undertakings in the arena of oncology have stemmed in the unearthing of numerous biomarkers, which are promising the growth of the market. These biomarkers have been outlined to cure particular type of cancer, which is boosting up the market.
Procedures such as immunofluorescence, ELISA, chemiluminescence, and others have turned out to be a dominant tool for ailment diagnosis. At present radioimmunoassay finds use merely in hormone testing and cancer testing, where advanced level of accurateness is looked-for. Nevertheless, the execution area is anticipated to amplify with improved research and development goings-on. The requirement for multiplex ELISA is likewise rising on account of its advantage of analysing a sample for various biomarkers in a sole assay cycle. The requirement for multiplex ELISA is estimated to leave behind other procedures in cancer diagnosis as it needs a smaller amount of sample.
The greater occurrence of dengue, malaria, typhoid, tuberculosis, and cancer in developing economies is posing as an opening in the immunoprotein diagnostic testing market. In addition, the population of nations in South East Asia is high, which is advantageous for the market. Budget friendly diagnostic tools for communicable diseases are significantly in demand in these areas. Intrinsically, the immunoprotein diagnostic testing market is estimated to observe a sharp growth as a result of plentiful opportunities offered by the emergent markets of Asia Pacific.